Asana Bio Sciences
Pharmaceuticals, 400 Crossing BLVD Fl 3, Lawrenceville, New Jersey, 08807, United States, 11-50 Employees
Phone Number: 19*********
Who is ASANA BIOSCIENCES
Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet ...
Read More
-
Headquarters: 400 Crossing BLVD Fl 3, Lawrenceville, New Jersey, 08807, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ASANA BIOSCIENCES
Asana BioSciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Asana BioSciences
Answer: Asana BioSciences's headquarters are located at 400 Crossing BLVD Fl 3, Lawrenceville, New Jersey, 08807, United States
Answer: Asana BioSciences's phone number is 19*********
Answer: Asana BioSciences's official website is https://asanabiosciences.com
Answer: Asana BioSciences's revenue is $1 Million to $5 Million
Answer: Asana BioSciences's SIC: 2836
Answer: Asana BioSciences's NAICS: 541714
Answer: Asana BioSciences has 11-50 employees
Answer: Asana BioSciences is in Pharmaceuticals
Answer: Asana BioSciences contact info: Phone number: 19********* Website: https://asanabiosciences.com
Answer: Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asanas lead immunology asset, is entering phase 3 development. Asanas lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asanas portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month